IsoPlexis Announces Closing of Public Offering

Rhea-AI Summary

IsoPlexis Corporation has successfully closed its initial public offering of 8,333,000 shares of common stock at $15.00 per share, raising gross proceeds of $125 million. The shares began trading on Nasdaq under the ticker symbol "ISO" on October 8, 2021. Notably, all shares in this offering were offered by IsoPlexis itself. The offering was led by Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink, with a registration statement declared effective by the SEC on October 7, 2021.

Positive

• Raised $125 million to support growth initiatives and product development.
• Shares began trading on Nasdaq under symbol 'ISO', improving visibility and market access.
• Strong backing from prominent underwriters including Morgan Stanley and Cowen.

Negative

• Potential dilution of existing shares due to the public offering.

BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IsoPlexis, were $125.0 million. IsoPlexis' common stock began trading on The Nasdaq Global Select Market on October 8, 2021, under the ticker symbol "ISO." All shares in the offering were offered by IsoPlexis.

Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting as lead book-running managers for the offering.

A registration statement on Form S-1 relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on October 7, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at prospectus@morganstanley.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com. Copies of the final prospectus related to the offering will be available at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IsoPlexis

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies by revenue and by nearly half of comprehensive cancer centers in the U.S.

Investor Contact
investors@isoplexis.com

Press Contact
press@isoplexis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/isoplexis-announces-closing-of-public-offering-301398547.html

SOURCE IsoPlexis

FAQ

What was the public offering price of IsoPlexis stock?

The public offering price for IsoPlexis stock was $15.00 per share.

How much money did IsoPlexis raise from its initial public offering?

IsoPlexis raised gross proceeds of $125 million from its initial public offering.

When did IsoPlexis begin trading on Nasdaq?

IsoPlexis began trading on Nasdaq on October 8, 2021.

Who were the lead underwriters for IsoPlexis' public offering?

The lead underwriters for IsoPlexis' public offering included Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink.